Literature DB >> 12665519

Beta-secretase cleavage at amino acid residue 34 in the amyloid beta peptide is dependent upon gamma-secretase activity.

Xiao-Ping Shi1, Katherine Tugusheva, James E Bruce, Adam Lucka, Guo-Xin Wu, Elizabeth Chen-Dodson, Eric Price, Yueming Li, Min Xu, Qian Huang, Mohinder K Sardana, Daria J Hazuda.   

Abstract

The amyloid beta peptides (Abeta) are the major components of the senile plaques characteristic of Alzheimer's disease. Abeta peptides are generated from the cleavage of amyloid precursor protein (APP) by beta- and gamma-secretases. Beta-secretase (BACE), a type-I transmembrane aspartyl protease, cleaves APP first to generate a 99-amino acid membrane-associated fragment (CT99) containing the N terminus of Abeta peptides. Gamma-secretase, a multi-protein complex, then cleaves within the transmembrane region of CT99 to generate the C termini of Abeta peptides. The production of Abeta peptides is, therefore, dependent on the activities of both BACE and gamma-secretase. The cleavage of APP by BACE is believed to be a prerequisite for gamma-secretase-mediated processing. In the present study, we provide evidence both in vitro and in cells that BACE-mediated cleavage between amino acid residues 34 and 35 (Abeta-34 site) in the Abeta region is dependent on gamma-secretase activity. In vitro, the Abeta-34 site is processed specifically by BACE1 and BACE2, but not by cathepsin D, a closely related aspartyl protease. Moreover, the cleavage of the Abeta-34 site by BACE1 or BACE2 occurred only when Abeta 1- 40 peptide, a gamma-secretase cleavage product, was used as substrate, not the non-cleaved CT99. In cells, overexpression of BACE1 or BACE2 dramatically increased the production of the Abeta 1-34 species. More importantly, the cellular production of Abeta 1-34 species induced by overexpression of BACE1 or BACE2 was blocked by a number of known gamma-secretase inhibitors in a concentration-dependent manner. These gamma-secretase inhibitors had no effect on enzymatic activity of BACE1 or BACE2 in vitro. Our data thus suggest that gamma-secretase cleavage of CT99 is a prerequisite for BACE-mediated processing at Abeta-34 site. Therefore, BACE and gamma-secretase activity can be mutually dependent.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12665519     DOI: 10.1074/jbc.M209859200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  22 in total

1.  Statin treatment and a disease-specific pattern of beta-amyloid peptides in Alzheimer's disease.

Authors:  Kina Höglund; Steinar Syversen; Piotr Lewczuk; Anders Wallin; Jens Wiltfang; Kaj Blennow
Journal:  Exp Brain Res       Date:  2005-06-04       Impact factor: 1.972

2.  Advances in Drug Therapy for Alzheimer's Disease.

Authors:  Chuan-Cong Zhu; Si-Yu Fu; Yu-Xin Chen; Ling Li; Ruo-Lin Mao; Jian-Zhi Wang; Rong Liu; Yi Liu; Xiao-Chuan Wang
Journal:  Curr Med Sci       Date:  2021-01-11

3.  beta-site amyloid precursor protein cleaving enzyme 1 increases amyloid deposition in brain parenchyma but reduces cerebrovascular amyloid angiopathy in aging BACE x APP[V717I] double-transgenic mice.

Authors:  Michael Willem; Ilse Dewachter; Neil Smyth; Tom Van Dooren; Peter Borghgraef; Christian Haass; Fred Van Leuven
Journal:  Am J Pathol       Date:  2004-11       Impact factor: 4.307

4.  Familial Alzheimer's disease patient-derived neurons reveal distinct mutation-specific effects on amyloid beta.

Authors:  Charles Arber; Jamie Toombs; Henrik Zetterberg; Selina Wray; Christopher Lovejoy; Natalie S Ryan; Ross W Paterson; Nanet Willumsen; Eleni Gkanatsiou; Erik Portelius; Kaj Blennow; Amanda Heslegrave; Jonathan M Schott; John Hardy; Tammaryn Lashley; Nick C Fox
Journal:  Mol Psychiatry       Date:  2019-04-12       Impact factor: 15.992

Review 5.  Are N- and C-terminally truncated Aβ species key pathological triggers in Alzheimer's disease?

Authors:  Julie Dunys; Audrey Valverde; Frédéric Checler
Journal:  J Biol Chem       Date:  2018-08-24       Impact factor: 5.157

Review 6.  BACE and gamma-secretase characterization and their sorting as therapeutic targets to reduce amyloidogenesis.

Authors:  Neville Marks; Martin J Berg
Journal:  Neurochem Res       Date:  2009-09-17       Impact factor: 3.996

7.  Fluorophore-quencher based activatable targeted optical probes for detecting in vivo cancer metastases.

Authors:  Mikako Ogawa; Nobuyuki Kosaka; Michelle R Longmire; Yasuteru Urano; Peter L Choyke; Hisataka Kobayashi
Journal:  Mol Pharm       Date:  2009 Mar-Apr       Impact factor: 4.939

Review 8.  Is γ-secretase a beneficial inactivating enzyme of the toxic APP C-terminal fragment C99?

Authors:  Frédéric Checler; Elissa Afram; Raphaëlle Pardossi-Piquard; Inger Lauritzen
Journal:  J Biol Chem       Date:  2021-03-01       Impact factor: 5.157

9.  BACE1 inhibition induces a specific cerebrospinal fluid β-amyloid pattern that identifies drug effects in the central nervous system.

Authors:  Niklas Mattsson; Lawrence Rajendran; Henrik Zetterberg; Mikael Gustavsson; Ulf Andreasson; Maria Olsson; Gunnar Brinkmalm; Johan Lundkvist; Laura H Jacobson; Ludovic Perrot; Ulf Neumann; Herman Borghys; Marc Mercken; Deborah Dhuyvetter; Fredrik Jeppsson; Kaj Blennow; Erik Portelius
Journal:  PLoS One       Date:  2012-02-06       Impact factor: 3.240

10.  Identification of BACE2 as an avid ß-amyloid-degrading protease.

Authors:  Samer O Abdul-Hay; Tomoko Sahara; Melinda McBride; Dongcheul Kang; Malcolm A Leissring
Journal:  Mol Neurodegener       Date:  2012-09-17       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.